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Background: Limited data suggest that patients with atrial fibrillation (AF) and mitral regurgitation (MR) have reduced thrombembolic events 
compared with those without MR. We performed a post hoc analysis of clinical characteristics and outcomes in anticoagulated patients with AF with 
significant valvular disease (SVD).
methods: From ROCKET AF, 14,171 patients with and without SVD were analyzed. Those with mitral stenosis or artificial valves were excluded from 
the trial.
results: A total of 1992 (14 %) patients had SVD, often with combined lesions (89.6% MR +/- aortic stenosis or regurgitation). Etiology was 
calcific/degenerative in 40.4%, postinfarction and/or ischemic in 12.9%. SVD patients were older than no SVD patients (median 75 vs. 72 yrs; 
p<0.0001); there was no difference in CHADS2 score or prevalence of diabetes mellitus. SVD patients more often had persistent AF than paroxysmal 
and newly diagnosed or new onset AF (p=0.049), had a longer history of AF, less frequent prior stroke or TIA, and more frequently had prior use 
of VKAs, CHF, prior MI, peripheral vascular disease, COPD, reduced creatinine clearance, and previous CABG. Events rates for efficacy and safety 
outcomes are presented after multivariate analyses (Table). Warfarin and rivaroxaban patients were pooled.
conclusions: SVD in AF was relatively common in ROCKET AF. Patients with SVD had similar adjusted thromboembolic outcomes and ICH as 
compared with those with no SVD; however, they had a significantly higher risk of major bleeding. 
SVD
Events/
100 Pt-Yrs
(total events)
No SVD
Events/
100 Pt-Yrs
(total events)
HR(95% CI)
SVD vs. no SVD
P Value
Efficacy Outcomes (ITT population)
Stroke or SE 2.23 (88) 2.09 (487) 1.07 (0.85, 1.35) 0.58
Stroke, SE, or vascular death 5.20 (199) 4.31 (982) 1.09 (0.93, 1.27) 0.28
Stroke, SE, vascular death, or MI 6.36 (240) 4.99 (1128) 1.14 (0.99, 1.31) 0.072
Stroke 1.92 (76) 1.96 (458) 0.98 (0.77, 1.26) 0.89
Systemic embolism 0.32 (13) 0.14 (34) 2.02 (1.00, 4.08) 0.049
MI 1.51 (60) 0.90 (212) 1.32 (0.98, 1.78) 0.065
All-cause death 5.54 (212) 4.39 (1002) 1.09 (0.93, 1.26) 0.29
Safety Outcomes (safety on-treatment population)
Major or NMCR bleeding 18.24 (493) 14.16 (2431) 1.14 (1.03, 1.25) 0.011
Major bleeding 5.11 (156) 3.27 (625) 1.32 (1.10, 1.57) 0.0027
ICH 0.80 (25) 0.59 (114) 1.35 (0.87, 2.09) 0.18
